Use of aspirin associates with longer primary patency of hemodialysis grafts.

  title={Use of aspirin associates with longer primary patency of hemodialysis grafts.},
  author={B. Dixon and G. Beck and L. Dember and M. Vazquez and A. Greenberg and J. Delmez and M. Allon and J. Himmelfarb and B. Hu and T. Greene and M. Radeva and I. Davidson and T. A. Ikizler and G. Braden and J. Lawson and J. Cotton and J. Kusek and H. Feldman},
  journal={Journal of the American Society of Nephrology : JASN},
  volume={22 4},
  • B. Dixon, G. Beck, +15 authors H. Feldman
  • Published 2011
  • Medicine
  • Journal of the American Society of Nephrology : JASN
  • Extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs primary unassisted graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions of each component are unknown. Here, we analyzed whether use of aspirin at baseline associated with primary unassisted graft patency among participants in a randomized trial that compared ERDP/ASA and placebo in newly created grafts. We used Cox proportional hazards regression, adjusting for prespecified… CONTINUE READING
    36 Citations

    Figures, Tables, and Topics from this paper

    Explore Further: Topics Discussed in This Paper

    Thrombophilia and arteriovenous fistula survival in ESRD.
    • 52
    • PDF
    Anticoagulant and antiplatelet therapy in patients with chronic kidney disease: risks versus benefits review
    • 16


    Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts.
    • 55
    Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.
    • 197
    • PDF
    Prevention of thrombosis in patients on hemodialysis by low-dose aspirin.
    • 229
    Natural history of arteriovenous grafts in hemodialysis patients.
    • 191
    Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    • 164